Zogenix, Inc. (NASDAQ:ZGNX) most recently reported quarterly actual earnings per share of $-0.78 for the period ending on 2016-06-30. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $-0.78. The difference between the estimate and the actual EPS was $0 creating a surprise factor of 0%. Currently, the company has an impact score of 0. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0.31. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.
In taking a look at where the stock might be headed, analysts have a consensus price target of $20.5 on the shares. The most bullish brokerage firm has a $28 target, while the most bearish sees the stock headed towards $10. This is according to the 4 estimates taken into consideration by Zacks Research.
In terms of Buy/Sell recommendations, analysts have a consensus rating of 1.5. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 4 recommendations taking into account in order to arrive at this number. Of the 4, 3 have a Strong Buy rating and 0 are rating it a Buy.
Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company’s product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Sumavel DosePro and Zohydro are used for the treatment options available to patients and physicians in the United States. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. In May, 2012, it submitted a New Drug Application to the Food and Drug Administration (FDA).
Zogenix, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.